Search
Publications
For the subgroup Rare hereditary blood cancers:
GATA2 monoallelic expression underlies reduced penetrance in inherited GATA2-mutated MDS/AML.
Quality of Life and Symptoms
The goals of the SWG are:
To promote the evaluation of patient-reported outcomes (PROs) in hematology in daily clinical practice and in clinical trials.
EHA Guidelines by Topic
AL Amyloidosis
Guidelines for high dose chemotherapy and stem cell transplantation for systemic AL amyloidosis: EHA-ISA working group guidelines (2021)
Guidelines for non-transplant chemotherapy for treatment of systemic AL amyloidosis: EHA-ISA working group (2022)
Anemia
Recommendations regarding splenectomy in hereditary hemolytic anemias (2017)
Management of…
La Cantera coaching
Disease-orientated training courses for young clinicians and researchers, inspired by a world-renowned football academy model. Call for interest from SWGs
In 2025, EHA will fund an additional course based on the La Cantera model.
Addressing immunoglobulin shortages: EHA and EBA’s strategic recommendations at the EMA
In recent years, shortages of immunoglobulins (Ig) have become a growing concern in the European Union (EU). Since 2018, the European Medicines Agency (EMA)—the EU agency that evaluates and supervises medicines—has received an increasing number of shortage reports.
Read moreHematology Tutorials
Hematology Tutorials are courses aiming to provide laboratory and clinical hematologists with an integrated diagnostic and clinical work-up of hematological disorders.
Read morePublications
The EBMT/EHA CAR-T Cell Handbook
Editors: Nicolaus Kröger, John Gribben, Christian Chabannon, Ibrahim Yakoub-Agha, Hermann Einsele. 2022, ISBN 978-3-030-94352-3 ISBN 978-3-030-94353-0 (eBook).
EHA Ranking 2025
The information on this page is also available as a printable PDF. EHA Ranking 2025 — PDF version
Position
Company
Priority points
Corporate Level
1
Johnson & Johnson
1. 488,82
Platinum
2
Bristol Myers Squibb
1.